Skip to content

Effect of Capsella bursa-pastoris with placebo on abnormal uterine bleeding and quality of life in patients with uterine leiomyoma.

Comparison of Capsella bursa-pastoris with placebo in Menometrorrhagia and quality of life in patients with uterine leiomyoma.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20161226031582N1
Enrollment
120
Registered
2018-01-11
Start date
2017-12-22
Completion date
Unknown
Last updated
2019-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menometrorrhagia. Excessive and frequent menstruation with regular cycle

Interventions

Intervention 1: Intervention group: Treated with 500mg capsules containing Capsella bursa-pastoris extract and starch, they will be placed three times a day between meals at 10am, 5am and will sleep f

Sponsors

Ghoum University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Having a score more than 100 in Pictorial blood assessment chart Age between 18 to 50 years old The existence of uterine leiomyoma proven in ultrasound No use of any effective medication on menstrual bleeding such as: 0CP, ASA, anti-coagulant No regular use of special herbal remedy during the 2 weeks before the study No systemic disease such as :Thyroid, Hyperprolactinemia, Coagulopathy, hemoglobinopathy No abnormal pap smear No pregnancy No breast feeding

Exclusion criteria

Exclusion criteria: Incidence of surgical indications such as: abnormal bleeding disorder of vital signs, resistant anemia to usual treatments, severe anemia (hemoglobin below 7), acute pain, severe urinary symptoms or hydronephrosis The use of any hormone, anti-fibrinolytic or systemic glucocorticoid The use of Monoamine oxidase inhibitors allergy to the drug studied Pregnancy during the study Unwilling to continue participation in the study Incidence of side-effects requiring special treatment

Design outcomes

Primary

MeasureTime frame
Amount of Menstrual bleeding. Timepoint: One month before, first, second and third month after intervention. Method of measurement: Higam Chart.;Duration of Menstrual bleeding. Timepoint: One month before, first, second and third month after intervention. Method of measurement: Calendar.;Quality of life. Timepoint: Before and 3 months after intervention. Method of measurement: Menorrhagia questionnaire.

Secondary

MeasureTime frame
Size of uterine leiomyoma. Timepoint: Before and 3 months after intervention. Method of measurement: Ultrasound.;Side effects of medication. Timepoint: 3 months after intervention. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtiehsadat Danesh

Ghoum University of Medical Sciences

atiehsdanesh@gmail.com+98 25 3770 7843

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026